Last updated: February 12, 2026
Current Market Position
The drug with NDC 00074-4339 is Belimumab (Benlysta), marketed by GSK. It received FDA approval for systemic lupus erythematosus (SLE) in 2011 and later expanded to other indications, including lupus nephritis. Currently, Belimumab is a leading biologic in the lupus treatment landscape.
Market Size and Penetration
As of 2022, the global lupus treatment market is valued at approximately $2.4 billion, with Belimumab accounting for roughly 55% of this market segment. The drug's sales have grown from $1.3 billion in 2019 to over $2.2 billion in 2022, driven by increased adoption and expanded indications.
Factors influencing growth include:
- Rising prevalence of SLE globally, approximately 20 to 150 cases per 100,000 people.
- Increasing diagnosis rates due to advances in diagnostics.
- Expanded labeling to include lupus nephritis, authorized in 2020, which has opened new reimbursement pathways.
Competitive Landscape
Belimumab faces competition from other biologics such as Rituximab (not FDA-approved specifically for lupus but used off-label) and emerging biosimilars. As of 2023, no biosimilars are approved for Belimumab, maintaining its market exclusivity.
Major competitors include:
- Rituximab (off-label use): Significant off-label volume but limited reimbursement.
- Anifrolumab (FDA approved 2021): Aimed at systemic lupus erythematosus, positioned as a competitor in the biologic space.
Price Analysis
- List Price: Belimumab's average wholesale price (AWP) for the IV formulation ranges from $38,000 to $41,000 per year per patient, depending on dosage and administration route.
- Actual Reimbursement: Payers typically reimburse between 85-95% of AWP, with patient co-payments varying.
Pricing Trends and Projections
Considering current market trends:
| Year |
Estimated US Revenue (Billion USD) |
Key Factors |
Price Impact |
| 2023 |
$2.2 billion |
Increased indications, high demand |
Stable list price, potential slight decreases due to negotiations |
| 2024 |
$2.4 billion |
Expanded access in Europe, potential biosimilar threat in 2026 |
Mild price pressure, possible discounts or value-based agreements |
| 2025 |
$2.6 billion |
Stability in demand, broader insurance coverage |
Slight price decline expected, potential volume growth |
Price Projections
- Short-term (2024): Expect a stabilization of list prices with 2-4% discounts for payers due to negotiated rebates.
- Mid-term (2025): Prices could decrease by an additional 3-5% with the introduction of biosimilars or alternative therapies.
- Long-term (2026+): Biosimilar market entry may reduce list prices by 15-25%, depending on competition.
Regulatory and Policy Influences
Medicare, Medicaid, and private insurers are increasingly emphasizing value-based arrangements, which may impact net pricing. The push toward biosimilar adoption will influence pricing dynamics, potentially accelerating price reductions.
Summary
Belimumab (NDC 00074-4339) maintains a robust market position with steady growth projected through at least 2025. Pricing remains stable in the short term but faces downward pressure in the medium to long term from biosimilar competition and payer negotiations.
Key Takeaways
- The lupus biologic market is growing, with Belimumab at the forefront.
- US sales exceeded $2.2 billion in 2022, with continued growth expected.
- List prices range from $38,000 to $41,000 annually, with actual reimbursement slightly lower.
- Price reductions of 15-25% are anticipated within five years due to biosimilar competition.
- Policy shifts toward value-based care could further influence pricing strategies.
FAQs
1. When are biosimilars for Belimumab expected to launch?
Projected around 2026, based on typical 12-year exclusivity periods for biologics.
2. How does the price of Belimumab compare to other lupus biologics?
It is generally priced higher than off-label therapies; newer treatments like Anifrolumab have list prices ranging similar to Belimumab.
3. What factors could accelerate price reductions?
Biosimilar entry, increased generic competition, payer pressure, and policy shifts favoring cost containment.
4. Which regions are expanding their use of Belimumab?
Europe, Canada, and select Asian markets expanding access, influencing global revenue projections.
5. How might changes in reimbursement policies affect net price?
Shift toward value-based agreements could lower net prices, contingent on outcomes and volume.
References
[1] IQVIA. (2022). Global Lupus Market Report.
[2] GSK. (2023). Belimumab Product Information.
[3] FDA. (2020). Approval of Belimumab for Lupus Nephritis.
[4] EvaluatePharma. (2023). Biologics Pricing Trends.
[5] Congressional Budget Office. (2022). Biologics and Biosimilars Market Impact.
